Roivant Sciences: 62% of Brepocitinib patients achieved steroid-free quiescence at week 48 vs 20% placebo in pooled CLARITY data

Roivant Sciences reported pooled data from CLARITY-1 and CLARITY-2 trials showing 62% of patients on Brepocitinib 45 mg once-daily achieved steroid-free quiescence at week 48, compared with 20% on placebo (p<0.0001). Results were consistent across both studies.